19 July 2016
US drugs company Pfizer has entered into a manufacturing and licensing agreement with Russian pharmaceutical company NovaMedica.
Pfizer has proposed to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region.
The technology for production of more than 30 medicinal products from Pfizer’s portfolio will also be licensed to the Russian company.
In a press release, Pfizer and NovaMedica announced that the design, development and construction of the manufacturing plant are scheduled to begin in 2016, with the start of medicine production planned for 2020.
Petra Weil, regional president of Europe from Pfizer, said: “We contribute broadly to the modernisation of the Russian pharmaceutical industry, education in medicine and high-quality manufacturing and bringing innovation in the field of medicine.”
Brian Dovey, member of the board of directors of NovaMedica, said: “The strategic partnership with Pfizer provides a major boost toward NovaMedica’s goal of becoming a world-class leader in the fast-growing Russian pharmaceutical market.”
PrintMerry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
A Moscow region manufacturer of blood collection systems is expanding its capacity
22 January 2025
A biotechnology and medicine center has opened in Mordovia
22 January 2025
Long-term potential revealed for novel modifier gene therapy
21 January 2025
Binnopharm Group opened an office in Vietnam
21 January 2025